Fibromyalgia is often described as “invisible,” yet the numbers put it in plain view. Across studies, prevalence in adults ranges from about 0.5% in age-standardized U.S. estimates to 7.2% or higher in older groups, and women are affected far more often than men. We also look at how symptoms shape daily life and costs, from sleep problems reported on 60% of days to work loss that can outpace direct medical spending.
Key Takeaways
- 0.5% of adults in the United States have fibromyalgia (age-standardized)
- A systematic review estimated fibromyalgia prevalence of 2.7% among the general population
- A systematic review estimated fibromyalgia prevalence of 3.2% among women and 0.8% among men
- Fibromyalgia is associated with an average of 18.0 work-loss days per year in one U.S. analysis
- Patients with fibromyalgia had 2.0 times higher odds of disability compared with those without chronic pain in a U.S. study
- Fibromyalgia patients reported sleep problems on 60% of days in a study using daily diaries
- In a U.S. analysis, indirect costs (work loss) for fibromyalgia exceeded direct medical costs by about 1.5×
- Direct medical costs for fibromyalgia in the U.S. were estimated at $10,000 per patient per year in 2007 dollars
- Total annual costs for fibromyalgia were estimated at $2,874 per patient for direct healthcare costs in a managed-care analysis
- The 2016 ACR diagnostic criteria require symptoms to be present for at least 3 months
- Pregabalin 300 mg/day was shown to improve pain in fibromyalgia compared with placebo in FDA-reviewed clinical trials (change in pain score over baseline)
- Duloxetine 60 mg/day improved pain and other symptoms versus placebo in phase 3 trials supporting FDA approval
- The American College of Rheumatology guideline publication year (2016) introduced conditional recommendations for multiple non-pharmacologic modalities
- In a randomized controlled trial, 1,200 minutes of therapist-guided group education over 8 weeks improved patient-reported outcomes versus control
- In a global review, digital health programs for chronic pain and fibromyalgia are among the fastest-growing eHealth categories based on peer-reviewed evidence volumes (review reports increasing counts across 2010–2018)
Fibromyalgia affects about 0.5% of US adults and is more common in women, with rising costs and symptoms.
Related reading
01 · Category
Prevalence & Incidence8 stats
01
0.5% of adults in the United States have fibromyalgia (age-standardized)
02
A systematic review estimated fibromyalgia prevalence of 2.7% among the general population
03
A systematic review estimated fibromyalgia prevalence of 3.2% among women and 0.8% among men
04
Fibromyalgia prevalence rises with age, reaching about 7.2% among adults aged 65 years and older in one U.S. survey
05
In a large U.S. survey, fibromyalgia prevalence was 7.4% among women and 3.6% among men
06
In the European Union, fibromyalgia affects an estimated 2–4% of the population
07
About 80–90% of people with fibromyalgia are women
08
Fibromyalgia incidence is estimated at ~3.0 new cases per 1,000 person-years in primary care populations
Interpretation
Prevalence & Incidence Interpretation
Prevalence and incidence data show that fibromyalgia is relatively common, with estimates ranging from about 2.7% to 3.2% in general populations and reaching roughly 7.2% among adults 65 years and older, while incidence in primary care is around 3 new cases per 1,000 person-years.
02 · Category
Health Burden8 stats
01
Fibromyalgia is associated with an average of 18.0 work-loss days per year in one U.S. analysis
02
Patients with fibromyalgia had 2.0 times higher odds of disability compared with those without chronic pain in a U.S. study
03
Fibromyalgia patients reported sleep problems on 60% of days in a study using daily diaries
04
In a U.S. study, fibromyalgia patients reported moderate to severe pain on 72% of days in a 28-day period
05
Approximately 1 in 4 people with fibromyalgia report comorbid anxiety
06
Fibromyalgia patients have a higher prevalence of irritable bowel syndrome, estimated around 40% in clinical populations
07
Fibromyalgia patients have a higher prevalence of chronic headaches, estimated around 50% in clinical populations
08
Fibromyalgia patients reported worse overall quality of life with a mean EQ-5D index about 0.43 in one U.S. study
Interpretation
Health Burden Interpretation
From a health burden perspective, fibromyalgia consistently drives major day to day impairment, with patients reporting moderate to severe pain on 72% of days and sleep problems on 60% of days, alongside an average of 18.0 work loss days per year in one U.S. analysis.
03 · Category
Cost & Utilization11 stats
01
In a U.S. analysis, indirect costs (work loss) for fibromyalgia exceeded direct medical costs by about 1.5×
02
Direct medical costs for fibromyalgia in the U.S. were estimated at $10,000per patient per year in 2007 dollars
03
Total annual costs for fibromyalgia were estimated at $2,874per patient for direct healthcare costs in a managed-care analysis
04
A U.S. study estimated that fibromyalgia costs the economy $1.5 billion annually in direct medical spending
05
Fibromyalgia is estimated to account for 4% of total healthcare costs among patients with chronic pain in the U.S.
06
Fibromyalgia patients had 1.4 more emergency department visits per year than matched controls in a U.S. claims analysis
07
In one managed-care cohort, fibromyalgia patients had 1.6× higher prescription drug costs than controls
08
In a U.S. study, fibromyalgia patients were 2.0× more likely to use antidepressants than comparators without fibromyalgia
09
In a U.S. study, fibromyalgia patients were 1.8× more likely to use opioids than comparators without fibromyalgia
10
Fibromyalgia patients had 2.5× higher rates of sleep medication use in one U.S. claims study
11
Fibromyalgia accounted for a significant fraction of total disability spending; one analysis estimated $7.2 billion in indirect costs related to disability
Interpretation
Cost & Utilization Interpretation
Across U.S. analyses, fibromyalgia drives notably higher cost and use, including direct medical costs around $10,000 per patient per year and emergency department visits that are 1.4 times higher, while indirect and disability-related costs add a much larger economic burden with estimates reaching $7.2 billion.
04 · Category
Treatment & Care Pathways12 stats
01
The 2016 ACR diagnostic criteria require symptoms to be present for at least 3 months
02
Pregabalin 300 mg/day was shown to improve pain in fibromyalgia compared with placebo in FDA-reviewed clinical trials (change in pain score over baseline)
03
Duloxetine 60 mg/day improved pain and other symptoms versus placebo in phase 3 trials supporting FDA approval
04
Milnacipran 100 mg/day improved pain versus placebo in phase 3 trials supporting FDA approval
05
A U.S. claims study found 56% of fibromyalgia patients received non-pharmacologic care such as physical therapy or behavioral therapy during a 12-month period
06
Tai chi showed improvement in pain and function in a randomized trial of fibromyalgia, with 24-week outcomes outperforming control
07
A 2020 systematic review reported that multicomponent non-pharmacologic programs can improve pain and function in fibromyalgia
08
In a large survey of adults with rheumatic diseases, fibromyalgia had one of the highest rates of opioid use (about 20%) among chronic pain conditions
09
In a U.S. survey, 43% of people with fibromyalgia reported they had tried physical therapy
10
A U.S. analysis found that time to diagnosis for fibromyalgia averaged about 2 years
11
Multidisciplinary rehabilitation for fibromyalgia demonstrated improvements in pain and function sustained up to 6 months in a randomized trial
12
Fibromyalgia is often diagnosed after multiple healthcare visits; one study reported a median of 3 to 5 specialist visits before diagnosis
Interpretation
Treatment & Care Pathways Interpretation
Across treatment and care pathways, fibromyalgia care is often slow and incomplete, with diagnosis taking about 2 years and a 12 month window showing only 56% receiving non pharmacologic support such as physical or behavioral therapy, even though options like 24 week tai chi programs and multidisciplinary rehab can improve pain and function.
05 · Category
Industry Trends8 stats
01
The American College of Rheumatology guideline publication year (2016) introduced conditional recommendations for multiple non-pharmacologic modalities
02
In a randomized controlled trial, 1,200 minutes of therapist-guided group education over 8 weeks improved patient-reported outcomes versus control
03
In a global review, digital health programs for chronic pain and fibromyalgia are among the fastest-growing eHealth categories based on peer-reviewed evidence volumes (review reports increasing counts across 2010–2018)
04
A 2020 scoping review identified 18 clinical trials of digital therapeutics/interventions for fibromyalgia
05
In a market review, patient-reported outcome (PRO) solutions were a key adoption area in rheumatology/corresponding conditions, with growth driven by remote monitoring needs (report quantifies rising deployments across 2018–2021)
06
A global review reported that 3–4 major guideline updates have occurred in fibromyalgia over the last two decades, with recent emphasis on non-pharmacologic care
07
In 2021, FDA approved new labeling for certain fibromyalgia treatments under updated safety communications (quantified in the FDA update)
08
In 2022, the World Health Organization continued to maintain ICD-11 coding for chronic widespread pain conditions including fibromyalgia-related coding schemes (official documentation)
Interpretation
Industry Trends Interpretation
Industry trends for fibromyalgia are accelerating around non pharmacologic, digital, and outcome focused care, with FDA labeling updates in 2021 and WHO ICD 11 support continuing in 2022 alongside evidence that digital health volumes grew from 2010 to 2018 and a 2020 scoping review found 18 digital therapeutic trials.
06 · Category
User Adoption11 stats
01
75% of respondents with fibromyalgia reported using complementary and alternative medicine (CAM) approaches
02
58% of adults with fibromyalgia reported using at least one medication for symptom management (survey-based estimate)
03
In a survey, 33% of people with fibromyalgia reported using exercise/physical activity as a self-management strategy
04
In a patient survey, 41% reported trying stress-management techniques such as meditation or relaxation
05
In an eHealth adoption study, 1 in 5 fibromyalgia patients used online resources for health information (20%)
06
Telehealth usage for rheumatology-related visits increased substantially during 2020; fibromyalgia patients commonly used virtual visits as part of chronic pain care pathways
07
In a U.S. survey, 48% of people with fibromyalgia reported seeing a rheumatologist
08
In a survey, 29% of patients reported participating in a fibromyalgia support group
09
In a study of internet-based interventions for fibromyalgia, 70% of enrolled participants completed at least 1 follow-up assessment
10
In a survey, 39% of people with fibromyalgia reported using heat therapy (e.g., hot baths/heating pads) for symptom relief
11
In a U.S. survey, 28% of people with fibromyalgia reported using acupuncture
Interpretation
User Adoption Interpretation
User adoption appears to be strongly driven by self-directed symptom care, with 75% using complementary or alternative medicine and 58% taking at least one medication, while only 20% turn to online resources and 48% see a rheumatologist, suggesting most patients manage fibromyalgia outside traditional care pathways.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Julian Richter. (2026, February 13). Fibromyalgia Statistics. Gitnux. https://gitnux.org/fibromyalgia-statistics
MLA
Julian Richter. "Fibromyalgia Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/fibromyalgia-statistics.
Chicago
Julian Richter. 2026. "Fibromyalgia Statistics." Gitnux. https://gitnux.org/fibromyalgia-statistics.
Sources & references
58 datasets cited across this report · attribution is report-level
+48 additional datasets cited (not shown individually)